Second-Generation Antipsychotics in Adolescent Psychiatric Patients: Metabolic Effects and Impact of an Early Weight Change to Predict Longer Term Weight Gain.

Détails

Ressource 1Télécharger: 29297696.pdf (440.98 [Ko])
Etat: Public
Version: Author's accepted manuscript
ID Serval
serval:BIB_E2606312F994
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Second-Generation Antipsychotics in Adolescent Psychiatric Patients: Metabolic Effects and Impact of an Early Weight Change to Predict Longer Term Weight Gain.
Périodique
Journal of child and adolescent psychopharmacology
Auteur(s)
Vandenberghe F., Najar-Giroud A., Holzer L., Conus P., Eap C.B., Ambresin A.E.
ISSN
1557-8992 (Electronic)
ISSN-L
1044-5463
Statut éditorial
Publié
Date de publication
05/2018
Peer-reviewed
Oui
Volume
28
Numéro
4
Pages
258-265
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
To examine the metabolic profile of adolescents at baseline and to determine the potential predictive power of a 1-month weight gain (WG) on weight changes during longer term second-generation antipsychotic (SGA) treatment.
A retrospective chart review study, including patients between 13 and 18 years of age and treated with SGA, was conducted. Available data at baseline, 1, 3, and 12 months of treatment were recorded.
Four hundred fifty-six patients were included, with a median age of 15 years. Ten percent of the patients were obese (>95th percentile) and abdominal obesity (>90th percentile) was observed in 12% of patients. In a subgroup of 42 patients with both baseline, 1, and 3-month weight data available, WG >4.5% after 1 month was found to be the best predictor (sensitivity: 100; specificity: 66; area under the curve: 83) for a WG >15% after 3 months. After adjusting for potential confounders, a threshold of WG >4% was found as being the best predictor.
A worrisome prevalence of metabolic disorders was observed in an adolescent psychiatric cohort. In such patients, a WG >4% during the first month of treatment should raise concerns about weight controlling strategies. Further research is needed to confirm the present results and to determine the impact of a 1-month WG on a 1-year weight change.
Mots-clé
Adolescent, Antipsychotic Agents/administration & dosage, Antipsychotic Agents/adverse effects, Female, Humans, Male, Metabolic Diseases/epidemiology, Obesity, Abdominal/epidemiology, Pediatric Obesity/epidemiology, Predictive Value of Tests, Retrospective Studies, Sensitivity and Specificity, Time Factors, Weight Gain/drug effects, metabolic syndrome, second generation antipsychotics, weight gain, weight monitoring
Pubmed
Web of science
Open Access
Oui
Création de la notice
11/01/2018 11:16
Dernière modification de la notice
20/08/2019 17:06
Données d'usage